Ovarian Cancer

During their lifetime, one in 70 women will receive a diagnosis of ovarian cancer, which is the second most common gynecologic cancer in the United States, according to Memorial Sloan Kettering Cancer Center.

The FDA granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of certain adults with epithelial ovarian, fallopian tube or primary peritoneal cancer.

Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.

September is Ovarian Cancer Awareness Month.

An off-the-shelf T-cell receptor therapy has shown promising early results in multiple solid tumor types, according to initial data from a phase 1 dose-escalation trial presented at ESMO Congress.

Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.

Submitted medical claims and out-of-pocket costs for genetic counseling encounters appeared relatively low among patients with certain cancer types, according to a research letter published in JAMA Health Forum.

Women who take aspirin frequently may reduce their risk for ovarian cancer, according to results of a meta-analysis published in Journal of Clinical Oncology.

A phase 3 trial of ofranergene obadenovec in platinum-resistant ovarian cancer failed to meet its primary endpoints of statistically significant improvement in PFS and OS, according to topline data released by the agent’s manufacturer.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.